Skip to main content

Table 2 Significantly changed secreted proteins in adipose tissue culture media and the corresponding identified genes in adipose tissue and liver tissue upon LPS-treatment

From: Comparative analysis of the human hepatic and adipose tissue transcriptomes during LPS-induced inflammation leads to the identification of differential biological pathways and candidate biomarkers

NAME

SYMBOL

AT FC-protein

avg AT LPS+ protein

avg AT LPS- protein

std AT LPS+ protein

std AT LPS- protein

AT (p val.) FC- transcriptome

LT (p val.) FC- transcriptome

Leukemia inhibitory factor

LIF

2.3

6, 6

2, 9

0, 22

0, 41

(0, 000) 7, 2

(ns) 2.9

Fractalkine

CX3CL1

4.3

4, 3

1, 0

0, 24

0, 10

(0, 000) 6.4

(ns) 9, 9

Tumor necrosis factor

TNF

3.8

4, 8

1, 3

0, 95

0, 15

(0, 000) 6

(ns) 1.7

Plasminogen activator inhibitor 2

SERPINB2

3.1

2, 6

0, 8

0, 41

0, 05

(0, 000) 6

(0, 002) 8

Interleukin-6

IL6

1.6

6, 9

4, 7

0, 31

0, 07

(0, 000) 4.5

(0, 01) 17.8

Pentraxin-related protein

PTX3

1.9

3, 5

1, 8

0, 70

0, 14

(0, 000) 4

(ns)2.1

Interstitial collagenase

MMP1

1.7

4, 7

2, 7

0, 16

0, 17

(0, 000) 3.4

(ns)-1.1

Tumor necrosis factor-inducible gene 6 protein

TNFAIP6

5.4

4, 8

0, 9

0, 95

0, 20

(0, 000) 3.1

(0, 000)17.9

Plasminogen activator inhibitor 1

SERPINE1

1.7

4, 0

2, 5

0, 19

0, 12

(0, 000) 3

(ns)1.7

C-C motif chemokine 2

CCL2

6.9

6, 9

1, 0

0, 11

0, 10

(0, 000) 2.3

(0, 004) 3.7

CD44 antigen

CD44

2.4

0, 3

0, 1

0, 01

0, 02

(ns) 1.7

(0, 000) 5.8

Insulin-like growth factor-binding protein 4

IGFBP4

-2.5

1, 4

3, 6

0, 10

0, 26

(ns)-1.1

(ns)1.2

Adipocyte enhancer-binding protein 1

AEBP1

-1.4

0, 2

0, 2

0, 00

0, 01

(ns)-1.2

(ns)1.2

Cystatin-C

CST3

-3.1

0, 8

2, 6

0, 06

0, 17

(ns)-1.2

(ns) -1.1

Versican core protein

VCAN

-2

0, 1

0, 2

0, 01

0, 01

(ns)-1.6

(ns) -1.4

Collagen alpha-1(VI) chain

COL6A1

-3.3

0, 4

1, 3

0, 27

0, 18

(ns)-1.6

(ns) -1.4

Transforming growth factor-beta-induced protein ig-h3

TGFBI

-2.5

0, 1

0, 1

0, 00

0, 01

(ns)-1.6

(ns) 1

Legumain

LGMN

-3.1

0, 9

2, 7

0, 06

0, 17

(0, 002)-2

(ns) 1.2

Gelsolin

GSN

-2.5

0, 1

0, 4

0, 03

0, 02

(0.002)-2

(ns) 1.1

Cathepsin B

CTSB

-1.2

2, 2

2, 7

0, 04

0, 04

(ns) -2

(ns) -1.2

Lysozyme C

LYZ

-3.3

0, 1

0, 3

0, 01

0, 04

(0, 001) -2.5

(ns) -3.3

Alpha-2-macroglobulin

A2M

-3.3

0, 3

1, 1

0, 04

0, 06

(0, 000) -3.3

(ns) -1.6

  1. Fold change (FC) for the significantly changed proteins (p ≤ 0.05, FC > 1.2) in adipose tissue (AT) n = 1 and the significantly changed genes (p ≤ 0.05, FC > 2, n = 7 for adipose tissue and n = 5 for liver tissue (LT)) is represented in bold, p value is given in brackets (...). The insignificantly affected genes (ns) are depicted in italics. FC was calculated in LPS treated samples (LPS+) compared to control samples (LPS-). Additionally, information about average (avg) value in proteomics experiment representative for protein expression and its standard deviation (std) are depicted in the table. The top candidate biomarkers related to inflamed adipose tissue are depicted in bold and underlined.
Back to article page

BMC Medical Genomics

ISSN: 1755-8794

Contact us